Bova UK has been sold to Vimian Group
Bova Holdings Limited
Established in 2017, Bova offers specialty pharmaceuticals covering a wide and expanding range of therapeutic areas such as gastrointestinal, antibiotics, ophthalmic and endocrine as well as various dosage forms including capsules, tablets, injections, oral liquids and transdermal creams. The company has more than 100 specialty pharmaceutical formulations for dogs, cats, horses and exotics. All raw materials and products are compliant with quality standards set out by regulatory authorities and the pharmaceuticals industry. Bova serves veterinary clinics and hospitals across the UK and in ten additional European markets through an online ordering system with deliveries within 24 hours. The company has a 1,800 square meter production facility in London covering sterile and non-sterile products, and employs 64 professionals within R&D, quality control, sales and manufacturing.
“The acquisition of Bova marks an important milestone in our strategic ambition to add new therapeutic areas to Vimian’s specialty pharma segment. Bova holds a unique position in the UK as the leading innovator in specialty pharmaceuticals for companion animal health and enjoys a strong financial position with high growth and high margins having grown with more than 70 percent over the past year. Tailor-made and customized specialty pharmaceuticals represent an attractive and fast-growing niche of the animal health market. We see significant opportunities for continued strong growth in the medium- to long-term perspective in UK as well as in other European markets,” said Magnus Kjellberg, Chief Executive Officer of Vimian’s specialty pharma segment, Nextmune.
“We are pleased to join Nextmune and Vimian’s home for entrepreneurs. We are dedicated to improving animal welfare by developing novel and innovative specialty pharmaceuticals in close collaboration with veterinarians and through this partnership we can realize our vision to become the leading companion animal health specialty pharmaceuticals company globally,” stated Nick Bova, Founder and Chief Executive Officer of Bova.
Roddy O’Neill, Managing Director and co-head of Lincoln’s U.S. Healthcare Group, added, “We are honored to advise the Bova UK team on the sale of the company to Vimian. The company has established a platform serving one of the fastest growing segments of the animal health market. We look forward to following the future success of the partnership between Bova UK and Vimian.”
Meet our Senior Team
Professionals with Complementary Expertise
View More Transactions in Healthcare
Lincoln International advised Aquiline Capital Partners on the acquisition of Health Prime from GPB Capital Holdings
Lincoln International advised Talisman Capital Partners on the sale of ADVOCATE RCM to Ventra Health, a portfolio company of Varsity Healthcare Partners
Lincoln International advised Mars on the sale of Diamond Animal Health to Veterinary Pharmaceutical Solutions, a portfolio company of Granite Creek Capital Partners
Lincoln International advised 7Mind on its sale to Gymondo, a portfolio company of Oakley Capital
Lincoln International advised Olive AI on the sale of substantially all of its assets to Waystar and Humata Health
Lincoln International advised EQT on the acquisition of a controlling stake in Indira IVF from TA Associates and promoter family
Lincoln International advised Scantox Group, a portfolio company of Impilo, on its acquisition of QPS Austria’s Neuropharmacology Division
Lincoln International advised Seven Hills Capital on raising capital for Reliable Medical
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.